Dr. Daniel T. Garber, M.D.
Sleep Medicine (Sleep Medicine (Psychiatry & Neurology) Physician)
- Medicare participating
At a glance
- Medical school
- Virginia Commonwealth University, School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 230
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Virginia Commonwealth University, School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Sleep Medicine (Psychiatry & Neurology) Physician primary
NC license 9700557 -
Neurology Physician
NC license 9700557
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Forsyth Medical Group, LLC (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 396
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 158 | 133 |
| Established patient office or other outpatient visit, 40-54 minutes | 64 | 47 |
| Established patient office or other outpatient visit, 20-29 minutes | 50 | 45 |
| Telephone medical discussion with physician, 5-10 minutes | 37 | 37 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 37 | 32 |
| Telephone medical discussion with physician, 11-20 minutes | 24 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
| Sleep study in sleep lab (6 years or older) | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Concord, NC | 53 |
| Zolpidem Tartrate Other prescribers in Concord, NC | 12 |
| Armodafinil | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $264 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $207 |
|---|---|
| Itamar Medical Inc | $31.92 |
| Avadel Cns Pharmaceuticals, LLC | $25.20 |
| Education | $147 |
|---|---|
| Food and Beverage | $117 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Aug 26, 2025 | Education XYWAV · NEUROLOGY · in-kind | $79.99 |
| Jazz Pharmaceuticals Inc. Aug 26, 2025 | Education XYWAV · NEUROLOGY · in-kind | $67.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 2 companies. The companies reported $473,627 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Alkermes, Inc. · Completed · NCT06555783 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Alkermes, Inc. · Completed · NCT06358950 - A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)
Takeda Pharmaceuticals U.S.A., Inc. - A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Takeda Pharmaceuticals U.S.A., Inc. · Recruiting · NCT06952699 - TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy
Takeda Pharmaceuticals U.S.A., Inc. - A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc. · Recruiting · NCT06767683 - A long-term extension study to evaluate the safety and tolerability of TAK-861 in participants with selected central hypersomnia conditions
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Alkermes, Inc. · Active, not recruiting · NCT06843590
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.